PT2361090E - Composições para o tratamento centrado de náusea e vómito mediado - Google Patents

Composições para o tratamento centrado de náusea e vómito mediado Download PDF

Info

Publication number: PT2361090E
Authority: PT; Portugal
Prior art keywords: vomiting; compositions; centrally mediated; treating; nausea
Prior art date: 2009-11-18

Application number

PT108053018T

Other languages

English (en)

Inventor

Fabio Trento

Daniele Bonadeo

Riccardo Braglia

Sergio Cantoreggi

Giorgia Rossi

Roberta Cannella

Original Assignee

Helsinn Healthcare Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-18

Filing date

2010-11-18

Publication date

2014-09-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2361090(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-11-18 Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa

2014-09-03 Publication of PT2361090E publication Critical patent/PT2361090E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines Containing Plant Substances (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Paints Or Removers (AREA)

PT108053018T 2009-11-18 2010-11-18 Composições para o tratamento centrado de náusea e vómito mediado PT2361090E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26247009P	2009-11-18	2009-11-18
US38270910P	2010-09-14	2010-09-14

Publications (1)

Publication Number	Publication Date
PT2361090E true PT2361090E (pt)	2014-09-03

Family

ID=43608757

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT108053018T PT2361090E (pt)	2009-11-18	2010-11-18	Composições para o tratamento centrado de náusea e vómito mediado
PT141516831T PT2722045T (pt)	2009-11-18	2010-11-18	Composições para o tratamento de náuseas e vómitos mediadas centralmente

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT141516831T PT2722045T (pt)	2009-11-18	2010-11-18	Composições para o tratamento de náuseas e vómitos mediadas centralmente

Country Status (39)

Country	Link
US (1)	US12042494B2 (pt)
EP (3)	EP2722044B1 (pt)
JP (1)	JP5890780B2 (pt)
KR (1)	KR101615108B1 (pt)
CN (6)	CN106421793B (pt)
AP (1)	AP3083A (pt)
AU (1)	AU2010320598B2 (pt)
BR (1)	BR112012011485B1 (pt)
CA (1)	CA2778301C (pt)
CL (1)	CL2012001276A1 (pt)
CO (1)	CO6551693A2 (pt)
CR (1)	CR20120216A (pt)
CU (1)	CU24048B1 (pt)
CY (1)	CY1118062T1 (pt)
DK (2)	DK2361090T3 (pt)
DO (1)	DOP2012000138A (pt)
EA (1)	EA026815B1 (pt)
EC (1)	ECSP12011907A (pt)
ES (4)	ES2595077T3 (pt)
GE (1)	GEP20156226B (pt)
GT (1)	GT201200156A (pt)
HK (2)	HK1214147A1 (pt)
HR (3)	HRP20140759T1 (pt)
HU (1)	HUE029677T2 (pt)
IL (1)	IL219576A (pt)
LT (1)	LT2722045T (pt)
MA (1)	MA33810B1 (pt)
MX (1)	MX2012005347A (pt)
MY (1)	MY159393A (pt)
NI (1)	NI201200090A (pt)
NZ (1)	NZ599439A (pt)
PE (1)	PE20121483A1 (pt)
PL (3)	PL2722045T3 (pt)
PT (2)	PT2361090E (pt)
RS (2)	RS55206B1 (pt)
SI (2)	SI2722045T1 (pt)
SM (1)	SMT201400112B (pt)
TN (1)	TN2012000170A1 (pt)
WO (1)	WO2011061622A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2722045B1 (en)	2009-11-18	2016-07-06	Helsinn Healthcare SA	Compositions for treating centrally mediated nausea and vomiting
CN106421793B (zh)	2009-11-18	2023-06-16	赫尔森保健股份公司	用于治疗中枢介导的恶心及呕吐的组合物及方法
US9782397B2 (en)	2011-07-04	2017-10-10	Irbm Science Park S.P.A.	Treatment of corneal neovascularization
CN106974912A (zh) *	2011-10-18	2017-07-25	赫尔辛医疗股份公司	奈妥匹坦和帕洛诺司琼的治疗性组合
US9403772B2 (en)	2011-11-29	2016-08-02	Helsinn Healthcare Sa	4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
US8426450B1 (en)	2011-11-29	2013-04-23	Helsinn Healthcare Sa	Substituted 4-phenyl pyridines having anti-emetic effect
CN103520725B (zh) *	2012-07-05	2017-10-24	海思科医药集团股份有限公司	一种治疗呕吐的药物组合物
CN106902086B (zh) *	2015-12-23	2020-10-20	江苏恒瑞医药股份有限公司	一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) *	2016-11-01	2016-12-14	Acacia Pharma Ltd	method
GB201702250D0 (en)	2017-02-10	2017-03-29	Acacia Pharma Ltd	Method
CN108721214B (zh) *	2017-04-14	2020-06-16	和龙	奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) *	2017-05-15	2018-11-23	和龙	奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) *	2017-07-04	2019-01-15	南京诺瑞特医药科技有限公司	含有奈妥吡坦的微乳制剂
MX2020005167A (es) *	2017-11-17	2020-08-20	Vanda Pharmaceuticals Inc	Metodo para el tratamiento de enfermedades gastrointestinales con tradipitant.
CA3089656A1 (en) *	2018-02-02	2019-08-08	Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro)	Oral formulations and uses thereof
EP4385500A1 (en)	2022-12-12	2024-06-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Fixed dose combination comprising netupitant and palonosetron
EP4385497A1 (en)	2022-12-12	2024-06-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2024126408A1 (en)	2022-12-12	2024-06-20	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2024126398A1 (en)	2022-12-12	2024-06-20	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Fixed dose combination comprising netupitant and palonosetron

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU642178B2 (en)	1989-11-28	1993-10-14	Roche Palo Alto Llc	New tricyclic compounds
US5510486A (en)	1994-07-26	1996-04-23	Syntex (U.S.A.) Inc.	Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en)	1995-11-10	2001-10-02	The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland	Calixarenes and their use for sequestration of metals
DE60014216T2 (de)	1999-02-24	2006-03-02	F. Hoffmann-La Roche Ag	4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
SI1303490T1 (sl)	2000-07-14	2008-10-31	Hoffmann La Roche	N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov
DK1349541T3 (da)	2000-12-14	2007-01-08	Hoffmann La Roche	Selvemulgerende lipidmatrix (SELM)
CA2505990C (en)	2002-11-15	2009-05-19	Helsinn Healthcare S.A.	Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en)	2003-01-30	2013-09-15	هيلسين هيلث كير أس ايه.	Liquid pharmaceutical formations of balloonosterone
TWI355936B (en)	2003-02-18	2012-01-11	Helsinn Healthcare Sa	Uses of palonosetron hydrochloride
CA2521369A1 (en) *	2003-04-08	2004-10-28	Progenics Pharmaceuticals, Inc.	The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
NZ560232A (en)	2005-02-25	2010-11-26	Hoffmann La Roche	Tablets with improved drug substance dispersibility
US7479312B2 (en)	2005-07-07	2009-01-20	Konica Minolta Opto, Inc.	Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) *	2005-11-18	2012-04-17	Scidose Llc	Lyophilization process and products obtained thereby
BRPI0708264A2 (pt) *	2006-02-23	2011-05-24	Pfizer Ltd	piperidinilpirrolidinas agonistas do receptor tipo 4 de melanocortina
JP5144527B2 (ja) *	2006-10-24	2013-02-13	ヘルシンヘルスケアソシエテアノニム	改良された安定性と生物学的利用能をもつ塩酸パロノセトロンの投与形態
US20110014117A1 (en) *	2007-06-28	2011-01-20	Schering Corporation	Anti-igf1r
CA2709827A1 (en) *	2007-12-18	2009-06-25	Schering Corporation	Biomarkers for sensitivity to anti-igf1r therapy
CN106421793B (zh)	2009-11-18	2023-06-16	赫尔森保健股份公司	用于治疗中枢介导的恶心及呕吐的组合物及方法

2010
- 2010-11-18 CN CN201610795827.5A patent/CN106421793B/zh active Active
- 2010-11-18 MY MYPI2012002073A patent/MY159393A/en unknown
- 2010-11-18 ES ES14151683.1T patent/ES2595077T3/es active Active
- 2010-11-18 EP EP14151678.1A patent/EP2722044B1/en active Active
- 2010-11-18 AU AU2010320598A patent/AU2010320598B2/en active Active
- 2010-11-18 PL PL14151683T patent/PL2722045T3/pl unknown
- 2010-11-18 PL PL10805301T patent/PL2361090T3/pl unknown
- 2010-11-18 WO PCT/IB2010/003106 patent/WO2011061622A1/en active Application Filing
- 2010-11-18 ES ES10805301.8T patent/ES2494015T3/es active Active
- 2010-11-18 ES ES14151676.5T patent/ES2559475T3/es active Active
- 2010-11-18 EP EP10805301.8A patent/EP2361090B1/en active Active
- 2010-11-18 JP JP2012539433A patent/JP5890780B2/ja active Active
- 2010-11-18 KR KR1020127015676A patent/KR101615108B1/ko active IP Right Grant
- 2010-11-18 SI SI201031291T patent/SI2722045T1/sl unknown
- 2010-11-18 CN CN201510047631.3A patent/CN104856999A/zh active Pending
- 2010-11-18 SI SI201030688T patent/SI2361090T1/sl unknown
- 2010-11-18 CN CN201610797549.7A patent/CN106512010A/zh active Pending
- 2010-11-18 DK DK10805301.8T patent/DK2361090T3/da active
- 2010-11-18 RS RS20160833A patent/RS55206B1/sr unknown
- 2010-11-18 CN CN2010800521070A patent/CN102655864A/zh active Pending
- 2010-11-18 RS RSP20140423 patent/RS53491B1/en unknown
- 2010-11-18 EP EP14151676.5A patent/EP2727590B1/en active Active
- 2010-11-18 BR BR112012011485-9A patent/BR112012011485B1/pt active IP Right Grant
- 2010-11-18 AP AP2012006278A patent/AP3083A/xx active
- 2010-11-18 PT PT108053018T patent/PT2361090E/pt unknown
- 2010-11-18 PE PE2012000686A patent/PE20121483A1/es active IP Right Grant
- 2010-11-18 CN CN201510046972.9A patent/CN104856998A/zh active Pending
- 2010-11-18 DK DK14151683.1T patent/DK2722045T3/en active
- 2010-11-18 PT PT141516831T patent/PT2722045T/pt unknown
- 2010-11-18 HU HUE14151683A patent/HUE029677T2/hu unknown
- 2010-11-18 LT LTEP14151683.1T patent/LT2722045T/lt unknown
- 2010-11-18 PL PL14151678T patent/PL2722044T3/pl unknown
- 2010-11-18 CN CN201610795817.1A patent/CN107050455B/zh active Active
- 2010-11-18 ES ES14151678.1T patent/ES2623503T3/es active Active
- 2010-11-18 GE GEAP201012752A patent/GEP20156226B/en unknown
- 2010-11-18 NZ NZ599439A patent/NZ599439A/en unknown
- 2010-11-18 MX MX2012005347A patent/MX2012005347A/es active IP Right Grant
- 2010-11-18 EA EA201290356A patent/EA026815B1/ru active Protection Beyond IP Right Term
- 2010-11-18 CA CA2778301A patent/CA2778301C/en active Active
2012
- 2012-04-13 TN TNP2012000170A patent/TN2012000170A1/en unknown
- 2012-04-26 CR CR20120216A patent/CR20120216A/es unknown
- 2012-05-03 IL IL219576A patent/IL219576A/en active IP Right Grant
- 2012-05-10 NI NI201200090A patent/NI201200090A/es unknown
- 2012-05-15 DO DO2012000138A patent/DOP2012000138A/es unknown
- 2012-05-16 CL CL2012001276A patent/CL2012001276A1/es unknown
- 2012-05-17 EC ECSP12011907 patent/ECSP12011907A/es unknown
- 2012-05-18 CO CO12082329A patent/CO6551693A2/es not_active Application Discontinuation
- 2012-05-18 GT GT201200156A patent/GT201200156A/es unknown
- 2012-05-18 CU CU2012000078A patent/CU24048B1/es active IP Right Grant
- 2012-06-11 MA MA34953A patent/MA33810B1/fr unknown
2014
- 2014-08-11 HR HRP20140759AT patent/HRP20140759T1/hr unknown
- 2014-08-18 SM SM201400112T patent/SMT201400112B/xx unknown
2016
- 2016-02-24 HK HK16102109.6A patent/HK1214147A1/zh unknown
- 2016-02-24 HK HK16102110.3A patent/HK1214148A1/zh unknown
- 2016-10-05 HR HRP20161277TT patent/HRP20161277T1/hr unknown
- 2016-10-05 CY CY20161100991T patent/CY1118062T1/el unknown
2017
- 2017-03-14 HR HRP20170419TT patent/HRP20170419T1/hr unknown
2022
- 2022-12-16 US US18/082,737 patent/US12042494B2/en active Active

Also Published As

Publication number	Publication date
EP2361090A1 (en)	2011-08-31
EP2722044A1 (en)	2014-04-23
CN102655864A (zh)	2012-09-05
CN106421793B (zh)	2023-06-16
MX2012005347A (es)	2012-08-03
TN2012000170A1 (en)	2013-12-12
ES2595077T3 (es)	2016-12-27
EA026815B1 (ru)	2017-05-31
ES2623503T3 (es)	2017-07-11
LT2722045T (lt)	2016-09-26
CU20120078A7 (es)	2012-10-15
NI201200090A (es)	2012-11-13
PL2722045T3 (pl)	2017-03-31
DK2361090T3 (da)	2014-08-25
IL219576A0 (en)	2012-06-28
CN104856998A (zh)	2015-08-26
GEP20156226B (en)	2015-01-26
SI2722045T1 (sl)	2017-02-28
KR20120101456A (ko)	2012-09-13
HRP20140759T1 (hr)	2014-10-24
HUE029677T2 (hu)	2017-03-28
CN107050455A (zh)	2017-08-18
CA2778301C (en)	2016-06-14
AP3083A (en)	2015-01-31
BR112012011485B1 (pt)	2021-06-29
SMT201400112B (it)	2014-11-10
EP2722044B1 (en)	2017-01-04
DOP2012000138A (es)	2012-11-15
MA33810B1 (fr)	2012-12-03
SI2361090T1 (sl)	2014-09-30
CN107050455B (zh)	2020-09-29
JP2013511507A (ja)	2013-04-04
ES2494015T3 (es)	2014-09-12
CR20120216A (es)	2012-07-24
EP2727590A1 (en)	2014-05-07
US12042494B2 (en)	2024-07-23
DK2722045T3 (en)	2016-10-24
AP2012006278A0 (en)	2012-06-30
EA201290356A1 (ru)	2012-12-28
US20230263799A1 (en)	2023-08-24
AU2010320598A1 (en)	2012-06-14
WO2011061622A1 (en)	2011-05-26
PL2722044T3 (pl)	2017-08-31
EP2361090B1 (en)	2014-05-21
CO6551693A2 (es)	2012-10-31
PL2361090T3 (pl)	2014-10-31
IL219576A (en)	2017-08-31
CY1118062T1 (el)	2017-06-28
HRP20161277T1 (hr)	2016-11-18
BR112012011485A2 (pt)	2018-04-03
HK1214147A1 (zh)	2016-07-22
EP2727590B1 (en)	2015-10-21
AU2010320598B2 (en)	2016-06-16
RS53491B1 (en)	2015-02-27
HRP20170419T1 (hr)	2017-06-02
CN106512010A (zh)	2017-03-22
KR101615108B1 (ko)	2016-05-12
PT2722045T (pt)	2016-10-18
CA2778301A1 (en)	2011-05-26
RS55206B1 (sr)	2017-01-31
HK1214148A1 (zh)	2016-07-22
ES2559475T3 (es)	2016-02-12
MY159393A (en)	2016-12-30
GT201200156A (es)	2014-03-27
NZ599439A (en)	2014-06-27
CN104856999A (zh)	2015-08-26
CN106421793A (zh)	2017-02-22
PE20121483A1 (es)	2012-12-02
CL2012001276A1 (es)	2012-12-07
JP5890780B2 (ja)	2016-03-22
ECSP12011907A (es)	2012-10-30
CU24048B1 (es)	2014-12-26

Publication	Publication Date	Title
HK1214147A1 (zh)	2016-07-22	用於治療中樞介導的噁心及嘔吐的組合物及方法
IL245734A0 (en)	2016-06-30	Methods and preparations to prevent abuse
EP2473042A4 (en)	2013-05-22	METHODS AND COMPOSITIONS FOR DESTROYING BIOFILM USING COMPOUNDS DERIVED FROM CHITOSAN
IL215932A0 (en)	2011-12-29	Compositions and methods for treating burns
EP2722045A3 (en)	2014-05-07	Compositions for treating centrally mediated nausea and vomiting
IL210097A0 (en)	2011-02-28	Compositions and methods for treating unfluenza
EP2504428A4 (en)	2013-09-25	METHOD AND COMPOSITIONS FOR TREATING OXALATE-MEDIATED SUFFERING
EP2429584A4 (en)	2013-02-20	TREATMENT PROCEDURE AND COMPOSITIONS
GB0903299D0 (en)	2009-04-08	Composition and methods
GB0912468D0 (en)	2009-08-26	Composition and method
EP2490536A4 (en)	2013-04-17	COMPOSITION AND METHOD
EP2294198A4 (en)	2011-10-19	METHODS AND COMPOSITIONS FOR ENHANCING PLANTS
GB0901494D0 (en)	2009-03-11	Compositions and Methods
EP2393506A4 (en)	2012-08-01	METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES
PL2263454T3 (pl)	2017-07-31	Kompozycja uzdatniająca
IL217764A0 (en)	2012-03-29	Methods and compositions for treating leukemia
EP2501672A4 (en)	2013-05-01	COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS
GB0901667D0 (en)	2009-03-11	Composition and method
ZA201203174B (en)	2013-02-27	Compositions for treating centrally mediated nausea and vomiting
HK1166017A1 (en)	2012-10-19	Compositions and methods for causing neurite outgrowth
GB0912714D0 (en)	2009-08-26	Composition and process
GB0907616D0 (en)	2009-06-10	Methods and compositions
GB0908498D0 (en)	2009-06-24	Compositions and methods
GB0909720D0 (en)	2009-07-22	Compositions and methods
IL219215A0 (en)	2012-06-28	Compositions and methods for treating aspergillosis